Ana
Fernández Montes
![Foto de Ana](/img/nophoto.png)
![Foto de Hospital Universitario Marqués de Valdecilla](/img/noimage_org.png)
Hospital Universitario Marqués de Valdecilla
Santander, EspañaPublicacións en colaboración con investigadores/as de Hospital Universitario Marqués de Valdecilla (19)
2024
-
Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?
British Journal of Cancer, Vol. 130, Núm. 5, pp. 777-787
-
Efficacy and safety of chemotherapy in young patients with advanced gastroesophageal adenocarcinoma: data from the Spanish AGAMENON-SEOM registry
Gastric Cancer, Vol. 27, Núm. 1, pp. 131-145
-
Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON–SEOM registry
Clinical and Translational Oncology
-
Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU
Revista espanola de enfermedades digestivas, Vol. 116, Núm. 2, pp. 83-113
-
Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU
Gastroenterologia y Hepatologia, Vol. 47, Núm. 4, pp. 401-432
2023
-
Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry
Journal of Cancer Research and Clinical Oncology, Vol. 149, Núm. 7, pp. 4077-4089
-
Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study
PLoS ONE, Vol. 18, Núm. 5 May
-
Real-World Outcomes in Patients with Metastatic Colorectal Cancer in Spain: The RWD-ACROSS Study
Cancers, Vol. 15, Núm. 18
-
The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy
Therapeutic Advances in Medical Oncology, Vol. 15
-
The Frequency of Specific KRAS Mutations, and Their Impact on Treatment Choice and Survival, in Patients With Metastatic Colorectal Cancer
Oncologist, Vol. 28, Núm. 10, pp. E902-E909
2022
-
External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study
Neuroendocrinology, Vol. 112, Núm. 1, pp. 88-100
-
Identification of Thrombosis-Related Genes in Patients with Advanced Gastric Cancer: Data from AGAMENON-SEOM Registry
Biomedicines, Vol. 10, Núm. 1
-
SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021)
Clinical and Translational Oncology, Vol. 24, Núm. 4, pp. 658-669
-
Sex and gender disparities in patients with advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry
ESMO Open, Vol. 7, Núm. 3
2021
-
Optimism and social support as contributing factors to spirituality in Cancer patients
Supportive Care in Cancer, Vol. 29, Núm. 6, pp. 3367-3373
2020
-
Optimal duration of first-line chemotherapy for advanced gastric cancer: data from the AGAMENON registry
Clinical and Translational Oncology, Vol. 22, Núm. 5, pp. 734-750
2019
-
Prognostic Nomogram and Patterns of Use of FOLFIRI-Aflibercept in Advanced Colorectal Cancer: A Real-World Data Analysis
Oncologist, Vol. 24, Núm. 8, pp. e687-e695
2018
-
Efficacy and safety of chemotherapy in older versus non-older patients with advanced gastric cancer: A real-world data, non-inferiority analysis
Journal of Geriatric Oncology, Vol. 9, Núm. 3, pp. 254-264
2016
-
On the effect of triplet or doublet chemotherapy in advanced gastric cancer: Results from a national cancer registry
JNCCN Journal of the National Comprehensive Cancer Network, Vol. 14, Núm. 11, pp. 1379-1388